The current price of MXCT is $1.31 — it has decreased by 5.76% since the previous close. Data as of Nov 5, 2026.
MXCT is down 23.39% over the past week, up 20.18% over the past month and down 10.88% over the past year. The price is above its 200-day moving average of $1.07.
Analysts' average 12-month price target for MXCT is $6.00, which implies 358.02% upside from the current price. Individual estimates range from $6.00 to $6.00.
Of the 6 analysts covering MaxCyte, Inc., 5 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
MaxCyte, Inc. has a market capitalization of $135.2M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, MaxCyte, Inc. posted a loss of $0.08 per share against an estimate of -$0.09, beating expectations by 11.11%. Upcoming reports are listed in the earnings calendar.
MaxCyte, Inc. reported revenue of $7.27M in its most recent quarter, which has decreased by 14.53% compared with the same quarter a year earlier. Analysts had expected $6.51M.
MaxCyte, Inc. has not paid any dividends over the past year.
In the latest trading session MXCT moved between $1.29 and $1.42, a range of 10.00% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of MaxCyte, Inc. shows a neutral rating today and a neutral rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for MaxCyte, Inc. is sell. Technical ratings are indicators, not investment advice.
Over the past 52 weeks MXCT has traded between $0.6434 and $1.81. The current price is 27.62% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.